The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
Dear Reader, thank you for your continued
support of this news service. As usual,
StratCom will take a break for the summer.
Monthly updates will resume in September.
Applied
Biosystems introduced the Veriti 96-Well Thermal Cycler that uses temperature-control
technology that is expected to increase the accuracy and efficiency of PCR
reactions. The technology used in
VeriFlex Blocks that enables researchers to determine optimal reaction
temperatures and perform simultaneous mixed-temperature reactions.
Aviva
Systems Biology’s ChIP-DSL (Chromatin
Immunoprecipitation-DNA Selection and Ligation) technology can detect virtually
all DNA-protein interactions with a limited cancer cell sample (106 cells). The
system was used to identify a set of 54 potential prognostic human breast
cancer biomarkers that correlate to the predicted outcome of estrogen receptor
(ER) treatment for breast cancer patients.
CombiMatrix Molecular Diagnostics launched the HemeScan bacterial artificial chromosome (BAC) array comparative
genomic hybridization (CGH)-based test for chronic lymphocytic leukemia (CLL). The test identifies all of the known
prognostic genomic imbalances relevant to the clinical course of CLL, including
deletions of 17p involving the p53 tumor suppressor gene and/or the deletion of
13q14.
Lab21 introduced a respiratory
virus panel for 20 respiratory viruses, including the common cold,
respiratory syncitial virus, and influenza A and B including H5N1, the subtype
linked to bird flu. The test takes
around six hours to complete, meaning test results can be returned to patients
in a day. The assay can discriminate
between viral and bacterial respiratory infections.
![[Page Banner Image]](images/hmole.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
